JDD Buzz Series | Algorithmic Beauty
A study in the September Journal of Drugs in Dermatology addressed the impact of social media algorithms on the perception of beauty. While the golden ratio dates back to ancient Greece – and is an ages-old beauty standard for those of European ancestry – beauty ideals of facial features often change over time and vary by region. Yet access to a curated diet of images through social media may …
A study in the September Journal of Drugs in Dermatology addressed the impact of social media algorithms on the perception of beauty. While the golden ratio dates back to ancient Greece – and is an ages-old beauty standard for those of European ancestry – beauty ideals of facial features often change over time and vary by region. Yet access to a curated diet of images through social media may … 
Syringomas are benign neoplasms derived from eccrine sweat glands. Eruptive syringomas are a subtype of syringomas and are typically located on the chest, neck, and abdomen during puberty or childhood. Herein, JDD authors Jennifer Wang BA, Nyousha Yousefi MD, Edward Heilman MD FAAD FCAP, and Jared Jagdeo MD MS present a 20-year-old African American female with an atypical case of eruptive syringom … 
The September edition of the Journal of Drugs in Dermatology (JDD) focuses on aesthetic treatments, exploring the latest advancements and innovative approaches that are reshaping dermatologic care. This month’s Editor's Picks bring together a selection of cutting-edge research, from the use of genomic analysis in melanoma management to AI’s influence on beauty standards.
Explore the latest … 
A study in the August Journal of Drugs in Dermatology addressed the burden of melasma – the populations most prone to melasma and the comorbidities associated with it. According to the study’s authors, a deeper understanding of the associations of race, ethnicity and comorbidities can help dermatologists determine which patients are at risk of developing melasma and as well as potential new pa … 
Semaglutide is a glucagon-like peptide-1 (GLP-1) analog that was FDA-approved in 2017 for treatment of type II diabetes and in 2021 for treatment for chronic weight management in adults with obesity or overweight with at least one weight-related condition.1 Due to its longer duration of action, it is typically administered subcutaneously once weekly. The safety profile of semaglutide is similar to … 